23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
---|---|---|---|---|
The Fight Against COVID19 | -0.28% | - | - | - |
^GSPC | +0.80% | +4.21% | +23.24% | +5574.74% |
Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | 146.67 | +1.39 | +0.96% | 4:00 p.m. EDT | 12.59M | 7.70M | 352.99B |
ABBV | AbbVie Inc. | 161.24 | +4.93 | +3.15% | 4:05 p.m. EDT | 15.00M | 5.78M | 284.73B |
PFE | Pfizer Inc. | 28.66 | +0.46 | +1.63% | 4:00 p.m. EDT | 75.01M | 42.12M | 162.40B |
SNY | Sanofi | 49.03 | +1.20 | +2.51% | 4:00 p.m. EDT | 1.78M | 1.98M | 122.55B |
REGN | Regeneron Pharmaceuticals, Inc. | 980.16 | +10.25 | +1.06% | 4:00 p.m. EDT | 808.76k | 440.60k | 108.00B |
GSK | GSK plc | 44.77 | +0.75 | +1.70% | 4:00 p.m. EDT | 3.37M | 3.12M | 91.29B |
GILD | Gilead Sciences, Inc. | 64.27 | +0.19 | +0.30% | 4:00 p.m. EDT | 14.10M | 7.04M | 80.07B |
MRNA | Moderna, Inc. | 142.55 | -8.94 | -5.90% | 4:00 p.m. EDT | 7.15M | 4.06M | 54.63B |
TAK | Takeda Pharmaceutical Company Limited | 13.35 | +0.32 | +2.46% | 4:00 p.m. EDT | 1.85M | 1.57M | 41.89B |
BNTX | BioNTech SE | 100.6 | +1.85 | +1.87% | 4:00 p.m. EDT | 1.56M | 723.66k | 24.24B |
NVAX | Novavax, Inc. | 15.03 | -0.22 | -1.44% | 4:00 p.m. EDT | 13.84M | 12.48M | 2.21B |
VIR | Vir Biotechnology, Inc. | 10.27 | -0.12 | -1.15% | 4:00 p.m. EDT | 828.23k | 889.63k | 1.40B |
INO | Inovio Pharmaceuticals, Inc. | 10.13 | +0.36 | +3.68% | 4:00 p.m. EDT | 254.67k | 427.41k | 262.48M |
J&J's Rybrevant is expected to generate $4bn in sales by 2030, as per GlobalData estimates.
COPENHAGEN, Denmark & MAINZ, Germany, June 01, 2024--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab in patients with PDL(1)-positive mNSCLC who had disease progression following one or more prior lines of anti-PD(L)1 containing treatment. The re